AGTX
Agentix Corp.
- PER (TTM)
- -
- PER (Forward)
- -
- EPS (TTM)
- -
- EPS (Forward)
- -
- PBR
- -0.46
- 시가총액
- 1.60M
- 배당수익률
- -
- 베타
- 0.90
- 1개월 수익률
- -2.44%
- 3개월 수익률
- -4.84%
- 6개월 수익률
- -10.55%
- 1년 수익률
- -20.10%
- 2년 수익률
- -
- 5일 평균거래량
- 5158
- 60일 평균거래량
- 2170
- 1년 평균거래량
- 11021
- 5d/60d 거래량 비율
- 2.38×
- 60d/1y 거래량 비율
- 0.20×
- 변동성(60일, 연환산)
- 60.89%
- BB 스퀴즈 스코어
- 0.65
- SMA50 비율
- 0.92
- SMA200 비율
- 0.98
- RSI (14)
- 42
- 20일 수렴도
- 0.06
- 52주 최고
- 0.05
- 52주 최저
- 0.02
- 고점 대비
- -20.10%
- 저점 대비
- 133.63%
펀더멘털 갱신: 2026-05-10T07:33:21+00:00 · 시세 갱신: 2026-05-10T06:07:52+00:00
회사 정보
Agentix Corp., a clinical development stage company, focuses on the development and commercialization of novel therapeutics to treat metabolic diseases in the United States. It develops AGTX-2004, a peripherally-acting CB1 receptor antagonist that has demonstrated efficacy in animal models of obesity and type 2 diabetes mellitus; and AGTX-2003, a peripherally-acting CB1 receptor inverse agonist, which has demonstrated efficacy in animal models of obesity and non-alcoholic fatty liver diseases. The company was formerly known as FairWind Energy, Inc. and changed its name to Agentix Corp. in June 2019. Agentix Corp. was founded in 2020 and is based in Dana Point, California.